Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic NSCLC

NCT03121417 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT03121417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03121417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic NSCLC
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Withdrawn
Start date
July 21, 2017
Completion date
March 9, 2019
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent non-small cell lung carcinoma, stage iv non-small cell lung cancer